{"Symbol": "CNCE", "AssetType": "Common Stock", "Name": "Concert Pharmaceuticals, Inc", "Description": "Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "65 Hayden Avenue, Lexington, MA, United States, 02421", "FullTimeEmployees": "70", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "281645152", "EBITDA": "-75635000", "PERatio": "None", "PEGRatio": "0", "BookValue": "4.855", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-3.347", "RevenuePerShareTTM": "0.237", "ProfitMargin": "0", "OperatingMarginTTM": "-11.0611", "ReturnOnAssetsTTM": "-0.262", "ReturnOnEquityTTM": "-0.5122", "RevenueTTM": "6417000", "GrossProfitTTM": "-58739000", "DilutedEPSTTM": "-2.629", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "129.347", "AnalystTargetPrice": "23.67", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "40.3086", "PriceToBookRatio": "1.9691", "EVToRevenue": "23.7953", "EVToEBITDA": "0", "Beta": "0.8462", "52WeekHigh": "12.24", "52WeekLow": "5.36", "50DayMovingAverage": "9.8667", "200DayMovingAverage": "9.606", "SharesOutstanding": "29678100", "SharesFloat": "22624188", "SharesShort": "766166", "SharesShortPriorMonth": "600547", "ShortRatio": "6.58", "ShortPercentOutstanding": "0.03", "ShortPercentFloat": "0.0284", "PercentInsiders": "9.152", "PercentInstitutions": "59.46", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}